http://www.acc.org/Feed?clinicalTopicID=3c5813ed-5b04-49ba-9134-96a6d8bfc120 Clinical Topic Feed: Heart Failure and Cardiac Biomarkers en /Latest-in-Cardiology/Journal-Scans/2026/03/19/17/12/Dobermann Two brief reports in JACC on the DOBERMANN-T and DOBERMANN-D trials found that among patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), early interleukin 6 (IL 6) receptor inhibition with tocilizumab safely reduced systemic inflammation but showed inconclusive effects on NT proBNP. In contrast, early dobutamine infusion did not lower NT proBNP levels but did reduce systolic blood pressure (SBP) without raising safety concerns. 1773942840000 Articles and Stories /Latest-in-Cardiology/Articles/2025/11/06/13/19/JACC-Journals-Publish-Latest-Science-From-aha-2025 AHA 2025 features key science simultaneously published across ACC's JACC Journals, including JACC, JACC: CardioOncology, JACC: Advances, JACC: Case Reports, JACC: Heart Failure and JACC: Cardiovascular Imaging. 1762527600000 Articles and Stories /Latest-in-Cardiology/Articles/2025/03/26/14/06/eagles-eye-view-26mar2025 In this week’s View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock. 1742998020000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2025/03/19/12/07/Does-Industry-Marketing-Lead-to-Increased-Rates-of-Prescribed-GDMT Guideline-directed medical therapy (GDMT), including angiotensin receptor-neprilysin inhibitors (ARNIs) and SGLT2 inhibitors, for treating heart failure with reduced ejection fraction (HFrEF) is underused. 1742412660000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2024/12/10/17/55/ntprobnp-and-cardiac-troponin How do N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) and I (hs-CTnI) predict long-term changes in cardiac structure and function in older adults? 1733806800000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2024/11/18/20/03/glp1-receptor-agonists-among What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27? 1731962340000 Articles and Stories /Latest-in-Cardiology/Clinical-Trials/2024/11/17/16/49/sarah The goal of the SARAH trial was to assess the efficacy of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan in preventing anthracycline-associated cardiotoxicity. 1731939300000 Articles and Stories /Latest-in-Cardiology/Articles/2024/11/13/21/17/mon-9am-endeavor-aha-2024 Myeloperoxidase inhibition with mitiperstat in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF, respectively) was safe and well-tolerated, but did not improve symptoms or exercise function... 1731938400000 Articles and Stories /Latest-in-Cardiology/Clinical-Trials/2024/11/17/16/35/endeavor The goal of the ENDEAVOR trial was to evaluate the effect of mitiperstat, a selective myeloperoxidase inhibitor, on symptom burden in patients with heart failure with preserved or moderately reduced ejection fraction (HFpEF or HFmrEF, respectively). 1731938400000 Articles and Stories /Latest-in-Cardiology/Articles/2024/11/01/01/42/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1730813820000 Articles and Stories